Gemifloxacin is effective in experimental pneumococcal meningitis.
In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Deltalog CFU/ml/h +/- standard deviation [SD], -0.25 +/- 0.09 versus -0.38 +/- 0.11; serum and CSF concentrations of gemifloxacin were 2.1 +/- 1.4 mg/liter and 0.59 +/- 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 +/- 1.4 mg/liter and 0.75 +/- 0.34 mg/liter, respectively, at 24 h) or activity (Deltalog CFU/ml/h +/- SD, -0.26 +/- 0.11).
Smirnov
A
A
Department of Neurology, University of Göttingen, Göttingen, Germany.
Wellmer
A
A
Gerber
J
J
Maier
K
K
Henne
S
S
Nau
R
R
D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000276:immunology / Q000382:microbiology; D004195:Disease Models, Animal; D024841:Fluoroquinolones; D000077735:Gemifloxacin; D006624:Hippocampus / Q000473:pathology; D008586:Meningitis, Pneumococcal / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009474:Neurons / Q000473:pathology; D011817:Rabbits; D013296:Streptococcus pneumoniae / Q000302:isolation & purification
D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D009287:Naphthyridines; D002443:Ceftriaxone; D000077735:Gemifloxacin